Intuitive Surgical (ISRG) Q4 2022 Earnings Call Transcript

Intuitive Surgical (ISRG 0.78%)
This autumn 2022 Earnings Name
Jan 24, 2023, 4:30 p.m. ET

Contents:

• Ready Remarks
• Questions and Solutions
• Name Contributors

Ready Remarks:

Operator

Women and gents, good afternoon. Thanks for standing by, and welcome to the Intuitive quarter 4 2022 earnings launch. At the moment, all strains are in a listen-only mode. Later, there might be a possibility to your questions.

[Operator instructions]. And as a reminder, right this moment’s convention is being recorded. At the moment, I might like to show the convention over to our host, head of investor relations, Mr. Brian King, please go forward.

Brian King — Head of Investor Relations

Good afternoon, and welcome to Intuitive’s fourth quarter earnings convention name. With me right this moment, we’ve Gary Guthart, our CEO; and Jamie Samath, our CFO. Earlier than we start, I wish to inform you that feedback talked about on right this moment’s name could also be deemed to include forward-looking statements. Precise outcomes could differ materially from these expressed or implied because of sure dangers and uncertainties.

These dangers and uncertainties are described intimately in our Securities and Alternate Fee filings, together with our most up-to-date Kind 10-Ok filed on February 3, 2022, and Kind 10-Q filed on October 21, 2022. Our SEC filings might be discovered via our web site or on the SEC’s web site. Traders are cautioned to not place undue reliance on such forward-looking statements. Please word that this convention name might be out there for audio replay on our web site at intuitive.com on the Occasions part underneath our investor relations web page.

At present’s press launch and supplementary monetary knowledge tables have been posted to our web site. At present’s format will include offering you with highlights of our fourth quarter outcomes as described in our press launch introduced earlier right this moment, adopted by a question-and-answer session. Gary will current the quarter’s enterprise and operational highlights. Jamie will present a evaluate of our monetary outcomes.

Then I’ll focus on process and scientific highlights and supply our up to date monetary outlook for 2023. And eventually, we’ll host a question-and-answer session. And with that, I’ll flip it over to Gary.

Gary Guthart — Chief Govt Officer

Thanks for becoming a member of us right this moment. The basics of our enterprise had been wholesome in This autumn and for the complete 12 months 2022. Process progress for the complete 12 months approached pre-pandemic ranges. Put in base progress was strong, and clients concurrently elevated utilization of present programs.

Our investments in product growth prolonged our multiport, single-port, and versatile robotics ecosystems via new instrument equipment, digital merchandise, and indication expansions. Lastly, the effective work of our operations groups and provide companions largely mitigated the provision chain challenges that persevered via the 12 months. Turning first to procedures. We noticed 18% process progress for the quarter and the complete 12 months.

Areas of energy included normal surgical procedure in america, notably benign procedures akin to bariatric surgical procedure, cholecystectomy, and hernia restore. Colon and rectal process progress additionally continued. Sturdy progress past urology exterior the U.S. was accretive to our international efficiency.

We attribute this diversification to the worth of our ecosystems and our strategic investments in group, scientific trials, knowledge merchandise, and market entry. Regionally, america, Japan, Europe, and India stood out within the quarter and 12 months. Process progress in China was hampered by the COVID wave in This autumn with procedures progressively declining beginning in November via the top of ’22. Ion procedures confirmed continued energy with 218% progress in ’22 in contrast with ’21, and SP procedures grew 38% over the identical interval, with the vast majority of its progress coming from Korea.

World core process areas of urology and gynecology moved towards restoration within the 12 months, each exceeding their three-year compound annual progress charges in ’22. On the capital entrance, we positioned 369 programs in This autumn in contrast with 385 in This autumn 2021. For the complete 12 months, we positioned 1,264 programs in contrast with 1,347 in ’21. Our put in base progress price was 12% for multiport, 149% for Ion, and 22% for SP in 2022.

Total, our capital placement traits confirmed sustained demand for extra capability in multiport and robust curiosity in increasing capability for Ion with a number of hospitals now working a number of Ion programs of their applications and variable demand for SP as we proceed to pursue our further indications. System utilization is a crucial predictor of future demand and utilization grew 5% for multiport within the 12 months and 10% for Ion. Utilization was roughly flat for SP over the 12 months, nonetheless, utilization elevated by 9% in This autumn measured 12 months over 12 months as our group included learnings. Relating our funds.

Income grew 9% in 2022. Income was impacted by the energy of the greenback within the 12 months and the decline of the trade-in inhabitants of third-generation multiport programs. Our bills landed on the increased finish of our spend steering reflecting continued R&D investments that assist the expansion of our platforms and digital merchandise, growth of our manufacturing and industrial capabilities, and capital amortization pushed by growth of our international footprint. Structurally, we’ve been rising our personal capital expenditures as we proceed to construct the corporate to provide the globe at industrial scale.

This is a crucial funding as a number of procedures utilizing our programs have change into the usual of care in a number of international locations. We have now been vertically integrating key applied sciences to develop a extra strong provide chain and convey essential merchandise to market at engaging value factors. These investments embody elevated possession of our imaging pipelines, strategic instrument and accent applied sciences, and software program and digital merchandise that enable us to serve our clients. The investments make our enterprise extra capital intensive than years previous, in assist of business dependability, a extra strong provide chain, and decrease product prices.

I might additionally prefer to take a second to stroll via our platform investments. Intuitive begins with the top in thoughts. Coordinating our efforts to allow our clients’ pursuit of the quadruple purpose in particular procedures, for instance, these generally surgical procedure. We design all our programs to permit for the addition of latest performance over time.

For our multiport platform, this design philosophy has enabled us to constantly strengthen our fourth technology da Vinci Xi by including new regulatory clearances, a brand new mannequin with the da Vinci X, new devices and equipment, new imaging capabilities, and new software program merchandise. These merchandise embody our stapling lot of devices, in addition to our superior vitality devices, which contributed roughly $890 million in income in ’22 with income progress of 18% within the 12 months and are a key enabler of the final surgical procedure progress mentioned a minute in the past. We added 65 consultant scientific process indications in america to our fourth-generation multiport platform since its launch. Our multiport indications now span six surgical classes and whole over 70 process indications for multiport platforms in america right this moment.

We routinely enhance our platform working programs with roughly 10 important fourth-generation OS releases since launch and dozens of smaller software program upgrades. We launched our next-generation Xi visualization, Endoscope Plus, and have been integrating digital merchandise, together with digital actuality coaching Intuitive Hub and the My Intuitive app. We count on to launch further Gen 4 appropriate merchandise and working system software program this 12 months. Concurrently, we put money into new generations of our multiport platform that deliver new and considerably enhanced capabilities.

For our multiport system growth applications, we prioritize as follows: our highest precedence is the advance of core surgical functionality concentrating on improved affected person outcomes, usually via innovation in robotic and instrument precision, imaging, and sensing whereas specializing in dependability and product high quality. Subsequent, we designed to enhance usability, care group’s talent acquisition, and analytic energy, together with digital merchandise for the working room, customized studying for care groups, and effectivity evaluation and providers for surgical applications. Subsequent, we designed platforms and their ecosystems that may decrease the full value to deal with per affected person episode. And eventually, we designed with the pliability so as to add future functionality to programs post-launch.

Given the time required to design and validate new architectures at any given second, we’re sometimes growing multiple system structure past that out there. Within the present international regulatory setting, core expertise adjustments usually require human scientific trials and substantial evaluate. These are multiyear funding cycles, and we’re making good progress. As we begin this 12 months, we don’t presently count on a brand new multiport system launch in 2023.

Turning to Ion. Adoption has been wholesome primarily based on its capacity to satisfy an unmet scientific want in lung biopsy. We’re centered on bettering the manufacturability, value, and robustness of iron merchandise to assist its fast progress within the U.S. We have now additionally submitted a regulatory file for a evaluate in Europe, Korea, and in China’s inexperienced channel.

We count on clearance in Europe in 2023. We do not have a agency forecast on the time for Ion clearance in China right now given pandemic-related changes ongoing within the Chinese language healthcare system. Ion can also be a platform with sturdy alternatives for future scientific purposes. We’re conducting superior growth and scientific analysis to increase Ion into different indications within the lung.

Whereas our Ion versatile robotics presents a possibility to supply worth within the physique exterior of lung, our focus is on finishing what we began for pulmonologists and thoracic surgeons. Our single-port platform, da Vinci SP, has supported sturdy adoption in Korea and has not too long ago obtained PMDA clearance with broad indications in Japan. We count on first installs of SP in Japan within the coming months. Subsequent, we plan to submit our file on da Vinci SP to our notified physique in Europe midyear 2023.

To this point, buyer suggestions on the scientific utility for SP has been wholesome with sturdy multi-specialty use of SP in Korea. In america, some indications have required potential scientific trials, and we’re presently conducting IDE trials in colorectal surgical procedure and thoracic surgical procedure. We’re pursuing further indications for SP past these two, and we’ll share extra info on these indications in 2023 as the necessities for our regulatory pathway for them are established. We’re persevering with to speculate important assets in R&D, the place the portfolio we’ve underneath growth is positioned to assist management in present classes and growth into new ones.

Our capital investments will enhance to assist provide chain robustness, product value discount, and international industrial scale. On the SG&A entrance, we’re making some foundational investments, and we’ll flip to pursue leverage in enabling capabilities. Recognizing financial situations for 2023 are onerous to forecast. We’re concentrating on a deceleration of mounted value progress price in ’23 relative to ’22.

We count on professional forma working margins to fluctuate within the subsequent a number of quarters after which enhance over the midterm. In closing, our priorities for 2023 are as follows: first, elevated adoption and centered procedures outlined by nation via excellent coaching, industrial, and market entry execution; second, pursuit of expanded indications and launches for our new platforms; third, glorious efficiency within the continuity of provide, product high quality, and providers provision as we emerge from pandemic stresses; and eventually, pursuit of elevated productiveness and our capabilities that profit from scale. I will now flip the time over to Jamie, who will take you thru our funds in higher element.

Jamie Samath — Chief Monetary Officer

Good afternoon. I’ll describe the highlights of our efficiency on a non-GAAP or professional forma foundation. I will even summarize our GAAP efficiency later in my ready remarks. A reconciliation between our professional forma and GAAP outcomes is posted on our web site.

This autumn and 2022 income and procedures are in keeping with our preliminary press launch of January 11. I’ll briefly evaluate full 12 months 2022 efficiency earlier than describing our This autumn leads to higher element. 2022 procedures grew by 18% as in comparison with 2021 or 15% on a three-year compound annual progress price foundation. In the course of the 12 months, we positioned 1,264 programs at clients, down 6% 12 months over 12 months, pushed by a decline in buying and selling volumes of 165 programs as a result of declining inhabitants of SIs within the discipline.

Recurring income, which is correlated to ongoing use of our merchandise, represented 79% of whole income and grew 15% over the prior 12 months. Complete income of $6.2 billion elevated 9% 12 months over 12 months and grew roughly 12% on a constant-currency foundation. Professional forma working margin was 35% of income and mirrored the affect of a number of headwinds, FX, provide chain challenges, and inflation collectively adversely impacted 2022 professional forma working margin by roughly 1 share level. In the course of the 12 months, we repurchased $2.6 billion of our inventory, or roughly 11.2 million shares, and we’ve a remaining authorization to repurchase our shares of $1.5 billion.

Turning to This autumn. With respect to capital efficiency, we positioned 369 programs, 4% decrease than the 385 programs we positioned within the fourth quarter of final 12 months. There have been 110 buying and selling transactions within the quarter as in comparison with 117 final 12 months. Fifty-one of the 110 buying and selling transactions had been with OUS clients, increased than latest traits primarily pushed by clients in Japan and Brazil.

As of the top of This autumn, there have been roughly 620 SIs remaining within the put in base, of which 134 are within the U.S. Given the persevering with decline of older technology programs within the discipline, we count on trade-in volumes to say no considerably in 2023. This autumn income was $1.66 billion, a rise of seven% from final 12 months. On a constant-currency foundation, fourth quarter income grew roughly 10%.

For full 12 months 2022, income denominated in non-USD currencies represented 24% of whole income. The U.S. greenback has weakened not too long ago, and because of this, on a revenue-weighted foundation utilizing present charges, the U.S. greenback is roughly 100 foundation factors stronger than the common charges realized in 2022.

Further income statistics and traits are as follows: Within the U.S., we positioned 181 programs within the fourth quarter, decrease than the 235 programs we positioned final 12 months, reflecting cautious capital spending by clients given the macroeconomic setting and the decline of 21 programs related to trade-in transactions. Common system utilization within the U.S. elevated by 6%, reaching an all-time excessive. Outdoors the U.S., we positioned 188 programs in This autumn in contrast with 150 programs final 12 months.

Present quarter system placements included 70 into Europe, 51 into Japan, and 14 into China in contrast with 63 into Europe, 37 into Japan, and 14 into China within the fourth quarter of 2021. As of the top of 2022, there have been 34 programs remaining underneath the present quota in China. There are actually 4 native opponents which might be registered in China, and they’re lively in tenders underneath the present quota. Delays within the granting of a brand new quota in China will constrain our capacity to additional develop the put in base and restrict capability for process progress.

Leasing represented 42% of This autumn placements in contrast with 37% final quarter and final 12 months. The upper lease combine was primarily pushed by the combination of consumers within the U.S. preferring to lease and mirrored, partially, a rise in placements acquired underneath usage-based preparations. Whereas leasing will fluctuate from quarter to quarter, we proceed to count on that the proportion of placements underneath working leases will enhance over time.

This autumn system common promoting costs had been $1.43 million as in comparison with $1.45 million final 12 months. System ASPs had been negatively impacted by FX, partially offset by a positive regional combine and a better mixture of Xi jewel placements. We acknowledged $17 million of lease buyout income within the fourth quarter in contrast with $17 million final quarter and $26 million in This autumn of 2021. Da Vinci instrument and accent income per process was roughly $1,820 in contrast with roughly $1,800 final quarter and $1,940 final 12 months.

On a year-over-year foundation, FX negatively impacted I&A per process by roughly $50 and buyer ordering patterns had a destructive affect of roughly $40 per process as clients, notably within the U.S. and China, decreased their stock ranges. Turning to our Ion platform. In 2022, we tripled procedures to simply over 23,000 and double system placements to 192 as in comparison with 2021.

In This autumn, we positioned 67 Ion programs as in comparison with 31 in This autumn of 2021. The put in base of Ion programs is now 321 programs, of which 132 are underneath working lease preparations. Fourth quarter Ion procedures of roughly 7,900 elevated 169% as in comparison with final 12 months. Leveraging earlier investments we’ve made in our da Vinci ecosystem through the quarter, we commenced the launch of My Intuitive app for Ion customers, offering them real-time entry and insights to their Ion utilization statistics.

Shifting on to the remainder of the P&L. Professional forma gross margin for the fourth quarter of 2022 was 68.2% in contrast with 70.1% for the fourth quarter of 2021 and 69.8% final quarter. As a reminder, final quarter’s gross margin included a one-time profit of roughly 50 foundation factors regarding the favorable conclusion of sure oblique tax issues. Professional forma gross margin was decrease than final 12 months, primarily on account of elevated mounted prices relative to income, the stronger U.S.

greenback, and better element pricing. The provision chain setting was difficult in This autumn, and indicators of provide and stock well being didn’t enhance as in comparison with final quarter. Greater mounted prices relative to income mirror a mixture of manufacturing-related inefficiencies given the setting and investments for future progress. Fourth quarter professional forma working bills elevated 19% in contrast with final 12 months, pushed by elevated headcount, increased journey prices, elevated buyer coaching actions, and better R&D-related mission prices.

Fourth quarter 2021 working bills included a $30 million contribution to the Intuitive Basis, which might assist their efforts for the following couple of years and didn’t repeat in 2022. The tempo at which we’re rising headcount continued to reasonable in This autumn with web additions of about 330 workers within the quarter in comparison with a web enhance of roughly 530 workers final quarter. Greater than half of the workers we added in This autumn had been manufacturing employees in our instrument manufacturing unit in Mexico to assist process progress. Whereas we’re slowing our hiring tempo and pursuing leverage in our enabling capabilities, we’re planning for balanced progress in working bills in 2023 given the chance to advance our next-generation robotics capabilities and the comparatively earlier stage of our investments in Ion, SP, and digital.

In 2023, we count on a big enhance in bills associated to scientific trials. Brian will present our outlook for working bills later on this name. As we stay up for our progress plans over the following a number of years, we’re planning to make important capital expenditures. Capital expenditures for 2022 had been $532 million, and we count on 2023 capital expenditures in a spread of $800 million to $1 billion, of which roughly two-thirds might be for amenities to broaden our manufacturing capability.

Our manufacturing funding plans embody superior proprietary amenities for manufacturing of latest merchandise and the Ion platform in California and da Vinci programs in Georgia. Internationally, we’re rising our product growth capability in Germany, constructing a brand new low-cost endoscope manufacturing facility in Bulgaria, and establishing manufacturing capability for home Xi manufacturing in China. We will even be increasing the footprint of our high-volume, low-cost instrument website in Mexico to assist process progress throughout all of our platforms. These investments enable us to consolidate our manufacturing into bigger centralized hubs, akin to our headquarter campus in Sunnyvale, California, and our East Coast hub simply exterior of Atlanta, whereas we’ll co-locate surgeon coaching, expertise growth, and manufacturing capability.

These are multiyear investments. And because of this, we count on depreciation expense to extend in 2023 and enhance extra considerably in 2024. Professional forma different earnings was $21.8 million for This autumn, increased than $7.2 million within the prior quarter, primarily on account of decrease overseas trade losses from remeasurement of the steadiness sheet and better curiosity earnings. Our professional forma efficient tax price for the fourth quarter was 18.2% decrease than prior quarters, primarily because of a extra favorable geographical earnings combine and a discrete tax advantage of $7 million related to the overseas tax matter.

Fourth quarter 2022 professional forma web earnings was $439 million or $1.23 per share in contrast with $473 million or $1.29 per share for the fourth quarter of final 12 months. I’ll now summarize our GAAP outcomes. GAAP web earnings was $325 million or $0.91 per share for the fourth quarter of 2022, in contrast with GAAP web earnings of $381 million or $1.04 per share for the fourth quarter of 2021. The changes between professional forma and GAAP web earnings are outlined and quantified on our web site and embody extra tax advantages related to worker inventory awards, worker stock-based compensation, amortization of intangibles, litigation fees, and positive aspects and losses on strategic investments.

We ended the 12 months with money and investments of $6.7 billion in contrast with $7.4 billion on the finish of Q3. The sequential discount in money and investments mirrored share repurchases of $1 billion and capital expenditures, partially offset by money from working actions. And with that, I wish to flip it over to Brian, who will focus on scientific highlights and supply our outlook for 2023.

Brian King — Head of Investor Relations

Thanks, Jamie. Total process progress for the complete 12 months 2022 was 18% and elevated 15% on a three-year compound annual progress foundation. Total process progress was comprised of 16% progress within the U.S. and 22% progress exterior of the U.S.

Within the U.S., fourth quarter 2022 procedures grew 18% 12 months over 12 months, in comparison with 16% for the fourth quarter of 2021 and 18% final quarter. The U.S. process progress price mirrored a positive comparability to the quarter a 12 months in the past, given the affect of the omicron variant in December of final 12 months. On a three-year compound annual progress foundation, U.S.

process progress was 13%. Outdoors of the U.S., fourth quarter process quantity grew roughly 18% 12 months over 12 months in comparison with 28% for the fourth quarter of 2021 and 24% final quarter. On a three-year compound annual progress foundation, process progress was 19%. Turning to Europe.

Process progress within the quarter was led by sturdy progress in U.Ok., Germany, and Italy. Within the areas famous, process progress exterior of urology was sturdy generally surgical procedure and gynecology classes. Particularly within the U.Ok., we skilled sturdy early stage progress in colorectal surgical procedure and continued sturdy progress in hysterectomy. Turning to Asia.

Progress exterior of China continued strong with notable energy in capital and process progress in Japan. Process progress in Korea was wholesome, and India and Taiwan proceed to expertise sturdy early stage progress. In Japan, as Jamie famous earlier, 51 programs had been positioned within the nation, essentially the most in a single quarter. Total process progress in Japan for the quarter was led by normal surgical procedure with sturdy early stage progress in colon resection and cystectomy and likewise in urology with newly reimbursed nephrectomy procedures.

In China, halfway via the fourth quarter, we noticed the decline in procedures. In the direction of the top of the quarter, we noticed a big decline in process quantity as hospitals had been coping with rising COVID instances as soon as the zero COVID coverage was eliminated. In consequence, China procedures skilled a modest year-over-year decline in This autumn. Now turning to the scientific facet of our enterprise.

Every quarter on these calls, we spotlight sure not too long ago printed research that we deem to be notable. Nevertheless, to achieve a extra full understanding of the physique of proof, we encourage all stakeholders to completely evaluate the intensive particulars of scientific research which have been printed through the years. Whereas nonetheless within the early phases of adoption within the U.S., robotic-assisted bariatric surgical procedure has been {one of the} fastest-growing procedures generally surgical procedure for Intuitive. In October 2022, the American Society for Metabolic and Bariatric Surgical procedure and Worldwide Federation for the surgical procedure of Weight problems and Metabolic Issues launched main updates to the 1991 Nationwide Institute of Well being pointers that beneficial reducing the BMI for metabolic and bariatric surgical procedure, or MBS, from 40 to 35, whatever the presence, absence, or severity of comorbidities.

These pointers word that, “MBS is now ideally carried out utilizing minimally invasive surgical approaches, laparoscopic robotic,” and that “MBS is the simplest evidence-based therapy for weight problems throughout all BMI lessons.” In one other bariatric evaluation, Dr. Wayne Barley from St. Luke’s College Hospital in Bethlehem, Pennsylvania, not too long ago printed a descriptive evaluation from the NBA SIP database figuring out the proportion of MBS procedures within the U.S. carried out between 2015 and 2020 utilizing a robotic or laparoscopic method and located as much as a threefold distinction within the proportion of assorted robotic-assisted MBS instances per 12 months.

We imagine our investments in superior devices and surgeon coaching are serving to to drive adoption of robotic-assisted surgical procedure in bariatrics. We stay up for persevering with to assist surgeons and their care groups as they supply high-quality robotic minimally invasive look after a good higher portion of the inhabitants underneath the brand new pointers. A latest rectal most cancers examine by Dr. Fang from Fudan College in Shanghai and on behalf of the RealStudy Group, printed short-term outcomes from a multicenter randomized managed trial within the Lancet.

This examine impaired robotic-assisted and laparoscopic approaches carried out by skilled surgeons for center and low rectal most cancers throughout 11 hospitals in China, with roughly 580 instances included in every method. With respect to perioperative outcomes, the speed of sufferers with a optimistic circumferential margin was 3.2% decrease within the robotic-assisted group, in addition to a 3.6% increased price of full macroscopic resection. Moreover, sufferers within the laparoscopic arm skilled a 2.2% increased price of conversion to open. A 3.3% increased price of intraoperative problems was additionally reported within the laparoscopic group.

Notably, 5.8% much less stomach perineal resections had been carried out within the robotic group. Postoperatively, sufferers within the robotic-assisted arm additionally had a sooner gastrointestinal restoration postoperatively, in addition to a one-day shorter size of keep and roughly 7% decrease price of postoperative problems with a Clavien-Dindo grade of two or increased. In abstract, the authors concluded that short-term outcomes recommend that for center and low rectal most cancers, robotic surgical procedure by skilled surgeons resulted in higher high quality resection than typical laparoscopic surgical procedure with much less surgical trauma and higher postoperative restoration. I’ll now flip to our monetary outlook for 2023.

Beginning with procedures. For 2023, we anticipate full 12 months process progress inside a spread of 12% to 16%. The low finish of the vary assumes continued choppiness with COVID hospitalizations and staffing stress at hospitals globally all year long. As well as, it assumes ongoing staffing, important challenges with COVID in China, and uncertainty with the timing of the brand new capital quota.

On the excessive finish of the vary, we assume no new important affect from COVID all through 2023, and assume continued progress generally surgical procedure within the U.S., and diversified progress past urology exterior of the U.S. The vary doesn’t mirror important materials, provide chain disruptions, or hospital capability constraints much like what we skilled firstly of the pandemic. Past the uncertainty with COVID in China, we count on related seasonal timing of procedures in 2023 as we’ve skilled earlier than the pandemic, with the primary quarter being the seasonally weakest quarter as affected person deductibles are reset. With respect to income, as we’ve talked about beforehand, capital gross sales are in the end pushed by process demand, catalyzing hospitals to ascertain or broaden robotic system capability.

Capital gross sales can differ considerably from interval to interval primarily based upon many elements, together with nationwide healthcare insurance policies, hospital capital spending cycles, reimbursement and authorities quotas, product cycles, financial cycles, and aggressive elements. Turning to gross revenue. Our full 12 months 2022 professional forma gross revenue margin was 69.2%. In 2023, we count on our professional forma gross revenue margin to be inside 68% and 69% of web income.

The decrease estimate of professional forma gross revenue margin in 2023 displays the affect of upper infrastructure funding prices, increased provide chain prices, and a higher combine of latest merchandise, specifically, from our Ion platform. Our precise gross revenue margin will differ quarter to quarter relying largely on product, regional and trade-in combine, process combine, and volumes, fluctuations in overseas foreign money charges, and the potential affect of aggressive pricing. Turning to working bills. In 2022, our professional forma working bills grew 23%.

In 2023, we count on professional forma working expense progress to be between 9% and 13%. The working expense progress displays investments to advance our platform capabilities, digital merchandise, together with continued growth into markets exterior of the U.S., and spending to assist regulatory clearances and scientific trials. We count on our noncash inventory compensation expense to vary between $610 million to $640 million in 2023. We count on different earnings, which is comprised principally of curiosity earnings to whole between $140 million and $160 million in 2023.

With regard to earnings tax, in 2022, our professional forma earnings tax price was 21.8%. As we glance ahead, we estimate our 2023 professional forma tax price to be between 22% and 24% of pre-tax earnings. That concludes our ready feedback. We are going to now open the decision to your questions.

Questions & Solutions:

Operator

[Operator instructions] Our first query right this moment comes from Robbie Marcus, representing J.P. Morgan. Please go forward.

Robbie Marcus — J.P. Morgan — Analyst

Nice. Respect it. Thanks for taking the questions. Possibly to start out, the opex information got here in loads higher than anticipated however steadiness that with taking it longer to get via the regulatory cycles and convey to market with a brand new robotic.

So, perhaps you would discuss what precisely is taking longer? Are there sure trials that perhaps hadn’t needed to be achieved up to now that are actually being required? And is that this a worldwide regulatory lengthening of time or are there particular markets which might be taking longer to return with a brand new robotic?

Gary Guthart — Chief Govt Officer

All proper. Thanks, Robbie. I believe we have been sharing with you over a number of quarters now, by way of new applied sciences and new indications, we have seen, in most of the core markets, not each single one, however a lot of them, further knowledge necessities. That modified most likely 4 years in the past, however has been taking part in right through.

So, it isn’t a lot that the setting has modified over that interval, simply the implications of that. And also you see that in issues like SP, our SP trials, 5 or 6 years in the past would have come to market in another way and so they’re requiring some potential human scientific work. That is not distinctive to SP. It actually has to do with what the underlying applied sciences are and what new indications could be.

So, I believe that’s taking part in via relative to prior iterations of programs and options. That is true. Definitely, in america, we have seen with the European regulatory adjustments through the years, elevated knowledge necessities in Europe after which it sort of varies by nation from there. By way of opex, maybe I will allow you to ask a follow-up query for Jamie on that one.

Robbie Marcus — J.P. Morgan — Analyst

Yeah. And Jamie, perhaps to observe up on the opex and I will tie in capex right here as a result of there’s a good funding there for the longer term. Possibly speak to the place you are seeing the lower in opex, SG&A versus R&D, and the place the decrease spending progress price 12 months over 12 months is coming from. Thanks.

Jamie Samath — Chief Monetary Officer

Yeah. It is truthful, Robbie, that we’re investing differentially throughout the areas of funding and the capabilities throughout the firm. Our priorities for ’23 with respect to working bills to drive progress within the areas of focus, and we’re being centered there. We’re trying to execute some alternatives to broaden markets by gaining further scientific indications and geographical clearances.

And clearly, we need to advance our expertise. Inside SG&A, what you see in subsets of the G&A capabilities is us trying to pursue leverage as we have described. And customarily, from an R&D perspective, there are some investments that, as Gary has beforehand referenced, we’re sequencing, and that is partly motivated by the way in which during which headcount has expanded over, for example, the final 12 months or two, and we have moderated our headcount progress as described, and that offers us the chance to soak up a few of that headcount. So, there’s differential funding inside SG&A and R&D.

If I take a look at R&D and SG&A sort of in combination, they’re prone to develop at comparatively related charges subsequent 12 months.

Robbie Marcus — J.P. Morgan — Analyst

Nice. Respect you taking the questions.

Operator

Then we’ll go to the road of Larry Biegelsen with Wells Fargo. Please go forward.

Larry Biegelsen — Wells Fargo Securities — Analyst

Good afternoon. Thanks for taking the query. One, in your — Gary, your new system feedback and one on the commercial scale feedback that you just made right this moment at JPMorgan. So, you talked about core expertise adjustments usually requiring the scientific trials and that you just will not launch a multiport system in 2023.

So, Gary, my query is: a, will you begin a scientific trial and a brand new system in ’23; and b, in the event you did begin a scientific trial, would you disclose that publicly even when the trial had been exterior the U.S., say, in a growing market?

Gary Guthart — Chief Govt Officer

Throughout our programs, we’re doing trials in all kinds of locations for all kinds of causes, whether or not it is SPI or in any other case. So, the reply there may be we’ve some locations the place these are publicly disclosed per regular guidelines. For aggressive causes, we do not attempt to element them an excessive amount of, and that is the place we’ll take going ahead.

Larry Biegelsen — Wells Fargo Securities — Analyst

Good. truthful sufficient. And Gary, you talked loads about — you used the time period industrial scale loads not too long ago. What does that imply precisely? And what are the implications for Intuitive financially? Thanks.

Gary Guthart — Chief Govt Officer

Now, I will take what does it imply, and I will ask Jamie to assist me on detailing on the finance facet. One of many issues that is occurring is that we have gotten well-integrated into many surgical practices in a number of international locations. I believe that is an incredible alternative for us and a severe accountability. As we have seen within the final couple of years with regard to provide chain robustness and different issues, ensuring that we’ve provide chain stability that we wish vertically integrating the place we are able to.

We have now been doing that. Loads of the imaging pipeline work that we have achieved. We predict that each provides us increased high quality. It permits us to decrease value to the shopper and it provides us robustness.

We will plan for that robustness. That is true not solely in imaging, however in some core applied sciences and devices and equipment. And we expect these are good long-term investments. In order that’s been actually optimistic.

There’s one other place the place our digital instruments and our digital merchandise, {one of the} issues that is occurring that I believe is highly effective for the corporate isn’t just product structure, however enterprise structure. And what I imply by that’s that our provide chain can assist a number of platforms in a number of international locations around the globe. It may well — by that, I imply, multiport, single-port, and Ion. Our digital merchandise structure is also seamless and may combine and assist these platforms.

So that offers us an incredible high quality benefit. It provides us a leverage functionality and permits us to decrease the full value for our clients and the fee to serve for our clients. These issues take some planning and a few ahead funding, and it may be in core expertise. For instance, in digital, it may be in amenities in manufacturing base so we are able to construct our merchandise.

But it surely’s that chance. It is a international alternative to assist assist the usual of care in a number of international locations. So, I believe that the shopper benefits are fairly clear. And I believe the fee robustness and long-term sturdiness benefits for the corporate are fairly clear.

However that takes some capital funding that can play out over time. Jamie, any show you how to’ll give?

Jamie Samath — Chief Monetary Officer

I might simply say industrial scale is linked to the capital expenditure plans that we have described, the $800 million to $1 billion of funding in ’23. I’d simply add the monetary ROI calculations on these investments are comparatively simple. And we expect there are actual benefits in having giant, extremely automated factories that run at scale and that is a bonus each for us and for our clients. So, the return calculations are comparatively simple and so they’re basically the incremental gross margin {dollars} we are able to drive from progress.

Larry Biegelsen — Wells Fargo Securities — Analyst

All proper. Thanks very a lot.

Jamie Samath — Chief Monetary Officer

Thanks, Larry. 

Operator

And subsequent, we’ll go to the road of Travis Steed with Financial institution of America. Please go forward.

Travis Steed — Financial institution of America Merrill Lynch — Analyst

Hello. Thanks for taking the query. Simply curious, Gary, I imply you talked about no new multiport platform in ’23, however curious the way you’re fascinated about upgrades to Gen 4, however that is principally simply across the software program upgrades you talked about, or if we may see one thing extra materials with functionality upgrades on {hardware} imaging or issues that deliver the shopper process down?

Gary Guthart — Chief Govt Officer

Yeah. We proceed so as to add capabilities into Gen 4. We count on to take action this 12 months as nicely. A few of it is going to be in superior instrumentation.

We’re performing some good work in our vitality programs each on the {hardware} facet and a few of the software program facet, and we expect there’s some functionality enhancements that we’ll be growing over time round core imaging functionality in Gen 4. So, we proceed to make progress.

Travis Steed — Financial institution of America Merrill Lynch — Analyst

OK. However not saying if something to return to ’23 or not on that entrance. After which whereas I’ve you, simply any early feedback on the capital funnel in ’23. I believe final 12 months, sort of January, February time-frame is when clients are evaluating funds.

So, I simply need to ensure that issues appear pretty steady with the capital funnel.

Jamie Samath — Chief Monetary Officer

On the capital funnel facet, what I might say is, given the macro inputs from clients, our sense is that they’re nonetheless comparatively cautious. I believe there’s fairly a little bit of uncertainty nonetheless within the macro. And whereas, for instance, staffing shortages have improved, they’re nonetheless fairly a bit worse than pre-pandemic ranges by way of labor prices, emptiness charges for hospitals. So, they’re being cautious from a monetary perspective and so they’re cautious given macroeconomic uncertainty.

I believe our experiences within the second half of ’22 has been the place clients are seeing good progress of their robotics applications. Da Vinci stays as a comparatively excessive precedence by way of their capital budgets. However past the truth that they’re cautious, I would not say there’s something particular I might spotlight by way of ’23 outlook.

Travis Steed — Financial institution of America Merrill Lynch — Analyst

Nice. Thanks.

Operator

And our subsequent query will come from the road of Rick Sensible with Stifel. Please go forward.

Rick Sensible — Stifel Monetary Corp. — Analyst

Good afternoon. Hello, Gary. Beginning off perhaps with the brand new system, thanks for being so clear about your ideas in regards to the timing of a brand new system, i.e., not in ’23. However at a excessive stage, may you speak to us about your fascinated about why or why not? I imply, I do know clearly, the corporate is to your whole historical past, you are at all times fascinated about what’s subsequent and preparing for it.

However how are you — is it the expertise that you just needed to have is not prepared but? Or that is extra about aggressive positioning or the tough exterior setting on capital makes you hesitant to go forward this 12 months? Simply attempting to know your fascinated about it and what that may say in regards to the future.

Gary Guthart — Chief Govt Officer

Yeah. Thanks for the query. We predict principally about what can we do this adjustments the expertise of surgical procedure for the affected person by way of outcomes and the care groups by way of how they ship that set of outcomes. And what we are able to do by way of expertise foundation, services and products and coaching that may assist that occur.

That’s the main factor. That is the factor that’s entrance and heart. And we do design research, analysis, usability effort, all of the belongings you would count on for us to make progress. After which we attempt to advance that as shortly as fairly we are able to given the setting that we’re in.

We do not do an excessive amount of perfection of timing about what we expect the hospital capital setting goes to be. We do not — you may think about anyone doing that, that’s not my highest motivation. I believe these items are subtle sufficient and sophisticated sufficient to deliver to market that attempting to time it completely with regard to the macroeconomic setting just isn’t what we’re actually pushed by. We work intently with our technologists who’re, I believe, spectacular.

We work intently with regulatory our bodies around the globe to know what their wants and necessities are. And naturally, we work very intently with key clients to know whether or not the issues we expect matter. And people are the issues that we actually do. And as soon as we discover a pathway, then we work down that pathway.

I’ve to say that provide chain disruptions which have occurred within the final three years have impacted not solely manufacturing functionality however affect new product growth as nicely as a result of that places waves and ripples into what sort of objects folks can procure for prototypes and different types of focus. So, there’s a little bit little bit of that in there, too.

Rick Sensible — Stifel Monetary Corp. — Analyst

Thanks. And simply as a follow-up, simply in the event you may broaden additional in your China feedback, notably associated to new tender quota expectations? And I simply need to ensure that I am understanding fastidiously or we’re all understanding your ideas or your embedded ideas about process restoration as circulation because the 12 months unfolds. Thanks very a lot.

Jamie Samath — Chief Monetary Officer

Yeah. I believe what we’re saying is we noticed China procedures impacted in November. That bought extra extreme in December, has continued to this point within the early a part of January, and we count on, due to this fact, procedures in China to be not less than impacted in Q1 and maybe past. And I believe it is tough for us to foretell, given the comparatively distinctive scenario China is in relative to the zero COVID coverage that they’ve had.

So, we’re not making any particular predictions as to when and the way that may recuperate. Brian laid out how that is mirrored within the process steering that we offered. Individually, on the quota, we’re within the third 12 months once more of sort of new quota interval, the final two quotas have been issued within the third 12 months. We solely use that as a historic reference, nothing extra.

We haven’t any explicit perception as to when a brand new quota would possibly come.

Rick Sensible — Stifel Monetary Corp. — Analyst

Thanks, Jamie.

Operator

And our subsequent query might be from the road of Matt Taylor with Jefferies. Please go forward.

Matt Taylor — Jefferies — Analyst

Hello. Thanks for taking the query. I needed to ask one on China. You talked in regards to the uncertainty with refreshing the quota after which some new native opponents which might be competing for tenders.

I questioned in the event you may sort of flesh that out a little bit bit and discuss any perception you’ve into when and the way a lot the quota could possibly be. After which may you give us a taste for a way aggressive you assume the native opponents might be to compete for the tenders in China and past?

Jamie Samath — Chief Monetary Officer

I might simply say that underlying demand for robotic expertise in China, in the event you take a mid- and long-term view is sort of sturdy. And our expertise to this point has been that surgeons care in regards to the functionality and have set of the merchandise that they use there. Once more, we haven’t any explicit perception with respect to timing and measurement of quota. We noticed the final quota we acquired was increased than the earlier one, however we’ve no capacity to foretell that it is going to be bigger once more.

So, we would love to have the ability to offer you higher readability than that. However what is the second a part of your query, Matt?

Gary Guthart — Chief Govt Officer

Why do not I take that one? That was a little bit bit about native competitors and what sorts of issues we’re seeing. First, I believe the entry of quota opponents in China is pure and ought to be anticipated. I believe in some methods, it is most likely a web optimistic by way of how folks take into consideration the quota. That is extra folks advocating for the worth of this out there, it is most likely a web optimistic over time, due to this fact, for market growth additionally.

Within the close to time period, early markets, we have seen this all over the place around the globe with new programs coming into — the very early entry is completely different than the center is completely different than the late. And the early, there are usually lots of placements, lots of issues round scientific trials, lots of issues round organising early capability which might be, in some sense, not indicative of value-based or feature-based competitors, and we’ll see a few of that early on. After which after that wave goes via placing your scientific trial programs out, then it begins to calm down, and also you see a little bit bit extra of what the core aggressive dynamics seem like. So, we’re actually, actually within the early innings with what we’re seeing in China opponents.

I count on them to be lively and assertive.

Matt Taylor — Jefferies — Analyst

OK, nice. Thanks for the colour.

Operator

Subsequent, we’ll go to the road of Anthony Petrone, representing the Mizuho Group. Please go forward.

Anthony Petrone — Mizuho Securities — Analyst

Thanks. One, on general pricing because it pertains to simply the replace right here on the multiport system after which a follow-up on process volumes, particularly within the U.S. On pricing, simply attempting to know the dynamics right here. We have now increased enter prices because it pertains to R&D.

There’s inflation, and there is a heavy capex cycle. So, you may form of, on the one hand, push that via the upper pricing for next-gen robotic. However on the opposite facet, we’ve, clearly, hospitals considerably constrained right here and Intuitive now has a licensing mannequin. So, once we take into consideration an elongated regulatory cycle, how does that affect the pricing technique on the next-gen robotic? After which simply shortly on procedures, the decrease BMI threshold, the brand new guideline, 40 to 35, it looks as if a giant deal.

Is that contemplated within the 12% to 16% process steering? Thanks.

Jamie Samath — Chief Monetary Officer

Simply with respect to pricing, I will solely touch upon present merchandise within the portfolio, as you described. What we’re seeing is core prices in our provide chain, the costs we pay our suppliers, the wage prices we pay our manufacturing employees. They’ve gone up, and that appears sticky. We have now a routine course of we use to observe pricing on an ongoing foundation.

We’ll proceed that course of. There’s nothing that we’d spotlight at this level with respect to any particular choices that we have made relative to pricing, but it surely’s one thing that we’re monitoring fastidiously via the present processes that we’ve. With respect to your query on bariatrics and the change in BMI pointers, I believe it is actually early to find out what impact, if something, that may have by way of the full surgical TAM for bariatrics. And so due to this fact, there’s nothing mirrored within the 12% to 16% steering that we offered, and I would not count on it to maneuver that shortly.

By the way in which, in bariatrics, there are sort of actual protocols sufferers should undergo with respect to a set of actions that they undertake earlier than they change into eligible for surgical procedure, even with this variation in pointers.

Gary Guthart — Chief Govt Officer

Possibly I might add a tiny bit on pricing and margin. On the pricing facet, we glance all the way in which throughout the full value of possession for our clients and be sure that’s matched to worth. So, what is the worth we deliver, after which what’s the pricing that does that? We do this, as Jamie mentioned, routinely, and we do it by nation. It is a international look.

With regard to a few of the pressures on margin, whether or not they’re inflationary or what have you ever, Jamie’s level, a few of these are sticky. We perceive the levers that we’ve, whether or not it is in design or scale or manufacturing, or different alternatives. And we’re in pursuit of these. I do not assume we’re confused about the place to go from right here.

A few of them take a short time. So, a few of the investments we’re making, a few of the automation that we talked about, a few of the manufacturing unit automation we’re speaking about, these are issues that give us higher management of value over time. And so, I do not assume we’re confused or actually caught off guard by a few of the adjustments of the fee affect.

Anthony Petrone — Mizuho Securities — Analyst

Thanks.

Operator

And we’ve a query from the road of Shagun Singh with RBC. Please go forward.

Shagun Singh — RBC Capital Markets — Analyst

Nice. Thanks for taking the query. Only a clarification after which one on Ion. On the brand new system, you mentioned not ’23, however may we count on one thing in ’24? Or if you need to provoke a scientific trial and relying on the scale of multiport are we taking a look at a launch past the ’24 timeline? Simply any preliminary shade can be useful.

And you then did speak in regards to the reducing the full value to deal with in addition to growth in several sorts of procedures. Any shade past what you offered on the decision on what sort of developments or any look into what may permit you to obtain that within the new system? After which on Ion, I used to be simply questioning in the event you may speak a little bit bit in regards to the anticipated affect of the complete set of the PRECISE two-year outcomes. And in addition, any progress that you just’re making on indication growth and the ablation expertise. Thanks for taking the query.

Gary Guthart — Chief Govt Officer

OK. Nothing additional to element on multiport past what we have mentioned already. With regard to alternatives for our platforms interval, we’ve alternatives throughout our set. I talked to you a little bit bit about what we’re doing in SP already.

We’ll element that extra because it unfolds in 2023 as to the place we see alternative for SP to create indication expansions and to open new process markets for us, which we’re enthusiastic about. On the Ion entrance, you requested a little bit bit in regards to the PRECISE tier knowledge. I haven’t got something extra to element on that. Suggestions from the sphere we’ve exterior of that particular examine has been that it is delivering on the promise.

People are discovering that it is usable, that it’s supplying the end result that they’d hoped and we’re seeing that mirrored within the adoption. So, we’re happy with that. With regard to ablation, we’re — as we mentioned final quarter, we’re simply on the early innings of partaking clients in Europe and looking out on the trial knowledge. We’re excited by it.

I believe there are a number of indications within the lung that we’ll pursue over time. We’ll element these extra as we get extra expertise and extra time. There are alternatives exterior the lung, too, I need to be clear. We predict these are fascinating, however they don’t seem to be areas of present focus.

We actually assume, end the job we began. We have now nice engagement with pulmonologists and thoracic surgeons. We have now the chance to proceed to assist them to make our merchandise ever simpler, extra strong, and to maneuver the margin construction the place we wish it to go. We will give attention to that.

After which we’ll transfer to different indications within the lung. After which from after that, we’ll have earned our alternative to do the following step. So, thanks for the questions there. That was our final query.

Shagun Singh — RBC Capital Markets — Analyst

Thanks.

Gary Guthart — Chief Govt Officer

In closing, we proceed to imagine there’s a substantial and sturdy alternative to basically enhance surgical procedure and acute interventions. Our groups proceed to work intently with hospitals, physicians, and care groups in pursuit of what our clients have termed the quadruple purpose: higher, extra predictable affected person outcomes; higher experiences for sufferers; higher experiences for his or her care groups; and, in the end, a decrease whole value of care. We imagine worth creation in surgical procedure and acute care is foundationally human. It flows from respect for and understanding of sufferers and care groups, their wants, and their setting.

At Intuitive, we envision a way forward for care that’s much less invasive and profoundly higher the place illnesses are recognized earlier and handled shortly so sufferers can get again to what issues most. Thanks to your assist on this extraordinary journey. We stay up for speaking with you once more in three months.

Operator

[Operator signoff]

Length: 0 minutes

Name individuals:

Brian King — Head of Investor Relations

Gary Guthart — Chief Govt Officer

Jamie Samath — Chief Monetary Officer

Robbie Marcus — J.P. Morgan — Analyst

Larry Biegelsen — Wells Fargo Securities — Analyst

Travis Steed — Financial institution of America Merrill Lynch — Analyst

Rick Sensible — Stifel Monetary Corp. — Analyst

Matt Taylor — Jefferies — Analyst

Anthony Petrone — Mizuho Securities — Analyst

Shagun Singh — RBC Capital Markets — Analyst

Extra ISRG evaluation

All earnings name transcripts